EC Healthcare provided consolidated earnings guidance for the year ended March 31, 2024. The board of directors of the Company informed the shareholders of the Company and potential investors that based on the latest assessment by the Board with reference to the preliminary unaudited consolidated management accounts of the Group for the year ended 31 March 2024 currently available, it is expected that the financial results of the Group may record: a decrease of not more than 10% in earnings before interests, taxation, depreciation-owned property, plant and equipment and amortization (EBITDA) for the Reporting Period as compared with the EBITDA of approximately HKD 430 million for the year ended 31 March 2023; and profit after tax (Net Profit) of not more than HKD 25 million for the Reporting Period, as compared with the Net Profit of approximately HKD 107 million for the year ended 31 March 2023. The Board believes that such year-on-year decrease in EBITDA and Net Profit during the Reporting Period was mainly attributable to: the increase in interest expenses from bank borrowings of approximately HKD 44 million due to the increasing interest rate comparing to the year ended 31 March 2023; temporary low operation leverage of their newly established service points comparing to the year ended 31 March 2023; the increase in depreciation and amortization expenses incurred from their organic expansion comparing to the year ended 31 March 2023; the increase in operating costs due to inflationary pressure; and the decrease of approximately HKD 43 million in subsidies from Hong Kong Government under the Employment Support Scheme.